Posted by Michael Wonder on 13 Jun 2023
Soliris approved in China for the treatment of adults with refractory generalised myasthenia gravis
13 June 2023 - Regulatory milestone marks third approval for Soliris in China, further expanding access to rare disease medicines
Soliris (eculizumab) has been approved in China for the treatment of adult patients with refractory generalised myasthenia gravis who are anti-acetylcholine receptor antibody positive.
